Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
INSIDE INFORMATION
REGULATED INFORMATION
Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
All 115 patients implanted in DREAM U.S. pivotal study
First DREAM PMA module submitted
First patient implanted in ACCCESS U.S. pivotal study
Mont-Saint-Guibert, Belgium – March 6, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has completed all 115 implants in its DREAM U.S. pivotal study, submitted the first module in the modular PMA submission and implanted the first patient in the ACCCESS U.S. pivotal study.
The DREAM study is a pivotal, investigational device exemption (IDE) trial designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States. This multicenter, prospective, open-label, observational study enrolled 115 patients and has co-primary efficacy endpoints of the Apnea-Hypopnea Index (AHI) responder rate, per the Sher criteria, and the Oxygen Desaturation Index (ODI) responder rate, both at 12 months.
In the ACCCESS trial, Nyxoah will implant 106 complete concentric collapse (CCC) patients with co-primary efficacy endpoints of Apnea-Hypopnea Index (AHI) responder rate, per the Sher criteria, and Oxygen Desaturation Index (ODI) responder rate, both assessed at 12 months post-implant.
“The achievement of these key clinical and regulatory milestones brings us closer to offering our patient centric Genio solution to all OSA patients in the U.S. The DREAM and ACCCESS studies demonstrate Nyxoah’s mission of providing Genio to patients regardless of CCC status and without the requirement for a CCC diagnosis,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; future financial performance and market position; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
David DeMartino
Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313
Attachment
- ENGLISH_Nyxoah Announces a Clinical Update
TIN LIÊN QUAN
THỦ THUẬT HAY
[Update 2022] Hướng dẫn download Office 365 full crack vĩnh viễn
Office 365 là một phần không thể thiếu trong việc học tập cũng như các công việc thường ngày. Bài viết sau đây, Vintech City sẽ hướng dẫn bạn đọc cách download Office 365 full crack. Mời bạn đọc cùng tìm hiểu.
Cách chỉnh sửa hậu kỳ bức ảnh sáng rõ và trong trẻo hơn bằng Camera Raw hoặc Lightroom
Các bạn khi chụp ảnh về thì dù cho có chụp kỹ và setup cẩn thận như thế nào thì bức ảnh cũng không thể nào đạt được chất lượng hoàn hảo nếu như chưa qua hậu kỳ chỉnh sửa. Quá trình hậu kỳ thật ra không có gì phức tạp
Hướng dẫn xem phim “Chuẩn rạp” ở nhà trên smart tivi Samsung?
Việc ngồi xem tivi không đúng khoảng cách sẽ khiến cho bạn dễ bị mỏi mắt và ảnh hưởng trực tiếp đến mắt. Vì vậy, để tăng trải nghiệm xem phim trên tivi Samsung và vừa giúp bảo vệ thị giác, thì bạn nên lựa chọn vị trí
Cách đem các trò cổ điển Solitaire và Minesweeper vào Windows 10
Windows 10, đã cải tiến nhiều, nhưng lại loại bỏ các trò chơi mà tất cả chúng ta đã từng thích lãng phí thời gian chơi. Song chúng được thay thế chúng bằng các phiên bản quảng cáo hỗ trợ nhanh hơn. Ví dụ trò Solitaire
[CHI TIẾT] Hướng dẫn download Foxit Reader Full crack trong vòng 5 phút
Download Foxit Reader full crack sẽ cho phép bạn sử dụng toàn bộ tính năng hữu ích của phần mềm này. Đây là một ứng dụng phổ biến dành riêng cho việc đọc file PDF và đã quá quen thuộc đối với người dùng máy tính. Trong
ĐÁNH GIÁ NHANH
[Đánh giá] Razer Lancehead TE: đối xứng và đằm tay, cảm biến xịn, phần mềm chưa hoàn chỉnh, giá cao
Razer Lancehead Tournament Edition (Lanchead TE) có thiết kế mới mẻ, thể hiện sự trở lại của đội 3 đầu rắn xanh với form đối xứng (ambidextrous) và sử dụng cảm biến tương tự DeathAdder Elite. Như tên gọi Tournament
Đánh giá nhanh về Galaxy Note 9 vừa được ra mắt
Bút S Pen được đánh giá là điểm sáng tại buổi ra mắt lần này, giờ đây sở hữu cả Bluetooth cho phép điều khiển từ cách xa 9m một số ứng dụng mặc định của máy, ví dụ như chụp ảnh từ xa, chiếu slide trong bài
Camera 360° Ricoh Theta V: Có đáng để nâng cấp với giá 10,99 triệu đồng
Theta V là chiếc camera 360° mới nhất, là bản nâng cấp đáng giá và được mong đợi nhất của chiếc Theta S và nó cũng là chiếc camera 360° dòng cao nhất của Ricoh cho đến bây giờ.